MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1038/s41375-018-0055-7

Медицинская библиотека · Leukemia · 2018

Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV.

Saussele Susanne, Hehlmann Rüdiger, Fabarius Alice, Jeromin Sabine, Proetel Ulrike, Rinaldetti Sebastien, Kohlbrenner Katharina, Einsele Hermann, Falge Christiane, Kanz Lothar, Neubauer Andreas, Kneba Michael, Stegelmann Frank, Pfreundschuh Michael, Waller Cornelius F, Oppliger Leibundgut Elisabeth, Heim Dominik, Krause Stefan W, Hofmann Wolf-Karsten, Hasford Joerg, Pfirrmann Markus, Müller Martin C, Hochhaus Andreas, Lauseker Michael

СтатьяРандомизированное исследованиеПоддержка исследования: вне правительства СШАПеревод пока не подготовлен

Аннотация

Major molecular remission (MMR) is an important therapy goal in chronic myeloid leukemia (CML). So far, MMR is not a failure criterion according to ELN management recommendation leading to uncertainties when to change therapy in CML patients not reaching MMR after 12 months. At monthly landmarks, for different molecular remission status Hazard ratios (HR) were estimated for patients registered to CML study IV who were divided in a learning and a validation sample. The minimum HR for MMR was found at 2.5 years with 0.28 (compared to patients without remission). In the validation sample, a significant advantage for progression-free survival (PFS) for patients in MMR could be detected (p-value 0.007). The optimal time to predict PFS in patients with MMR could be validated in an independent sample at 2.5 years. With our model we provide a suggestion when to define lack of MMR as therapy failure and thus treatment change should be considered. The optimal response time for 1% BCR-ABL at about 12-15 months was confirmed and for deep molecular remission no specific time point was detected. Nevertheless, it was demonstrated that the earlier the MMR is achieved the higher is the chance to attain deep molecular response later.

Для цитирования: Saussele Susanne, Hehlmann Rüdiger, Fabarius Alice, Jeromin Sabine, Proetel Ulrike, Rinaldetti Sebastien, Kohlbrenner Katharina, Einsele Hermann, Falge Christiane, Kanz Lothar, Neubauer Andreas, Kneba Michael, Stegelmann Frank, Pfreundschuh Michael, Waller Cornelius F, Oppliger Leibundgut Elisabeth, Heim Dominik, Krause Stefan W, Hofmann Wolf-Karsten, Hasford Joerg, Pfirrmann Markus, Müller Martin C, Hochhaus Andreas, Lauseker Michael. Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV.. Leukemia. 2018. DOI: 10.1038/s41375-018-0055-7.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.